Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats

Pharmacology Biochemistry and Behavior

Volumn 53, Issue 4, 1996, Pages 903-909

  Fujikawa, Maiko ^a   Nagashima, Mariko ^a   Inoue, Tsutomu ^a   Yamada, Katsushi ^b   Furukawa, Tatsuo ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

( ) 3 PPP; OPC 14597; Rotation; Stereotypy; Yawning; Adrenoceptor antagonists

Indexed keywords

7 [3 [4 (2,3 DIMETHYLPHENYL) 1 PIPERAZINYL]PROPOXY] 2(1H) QUINOLINONE; APOMORPHINE; ARIPIPRAZOLE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OXIDOPAMINE; PARTIAL AGONIST; PINDOLOL; PRECLAMOL; RESERPINE; TALIPEXOLE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; BRAIN INJURY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; INTRAPERITONEAL DRUG ADMINISTRATION; LICKING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SNIFFING; STEREOTYPY; SUBCUTANEOUS DRUG ADMINISTRATION; YAWNING;

ANIMALIA; POROMITRA OSCITANS;

EID: 0029867321     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/0091-3057(95)02096-9     Document Type: Article

References (41)

1. 2-antagonists of circling behaviour induced by dopamine agonists in rats with unilateral in 6-hydroxydopamine lesions. Eur. J. Pharmacol. 102:349-354; 1984.
2. Carlsson, M.; Carlsson, A.; Eriksson, E. The intrinsic activities of the partial dopamine receptor agonists (-)-3PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats. Eur. J. Pharmacol. 142:39-43; 1987.
3. Clark, D.; Hjorth, S.; Carlsson, A. Dopamine receptor agonists: Mechanism underlying autoreceptor selectivity. I. Review of the evidence, J. Neural Transm. 62:1-52; 1985.
4. Di Chiara, G.; Porceddu, M. L.; Vargiu, L.; Argiolas, A.; Gessa, G. L. Evidence for dopamine receptors mediating sedation in the mouse brain. Nature 264:564-567; 1976.
5. 2 receptor agonists on rotation behavior and dopamine receptor binding. Eur. J. Pharmacol. 236:385-393; 1993.
6. Fujikawa, M.; Yamada, K.; Nagashima, M.; Furukawa, T. Involvement of β-adrenoceptors in regulation of the yawning induced by neuropeptides, oxytocin and α-melanocyte-stimulating hormone, in rats. Pharmacol. Biochem. Behav. 50:339-343; 1995.
7. Gershanik, O.; Heikkila, R. E.; Duvoisin, R. C. Behavioral correlations of dopamine receptor activation. Neurology 33:1489-1492; 1983.
8. Gower, A. J.; Marriott, A. S. Pharmacological evidence for the subclassification of central dopamine receptors in the rats. Br. J. Pharmacol. 77:185-194; 1982.
9. 2 receptor sites. Eur. J. Pharmacol. 98:165-176; 1984.
10. 1 agonist SK&F 38393. Psychopharmacology (Berlin) 93:534-537; 1987.
11. Jerrold, C. W. Antipsychotic drugs (neuroleptics). In: Smith, C. M.; Reynald, A., eds. Textbook of pharmacology. Philadelphia: W. B. Saunders Company; 1992:299-308.
12. Kebabian, J. W.; Calne, D. B. Multiple receptors for dopamine. Nature 277:93-96; 1979.
13. Kimura, H.; Yamada, K.; Nagashima, M.; Matsumoto, S.; Ishii, Y.; Yoshida, S.; Fujii, K.; Furukawa, T. Role of adrenergic neuronal activity in the yawning induced by tacrine and NIK-247 in rats. Pharmacol. Biochem. Behav. 43:985-991; 1992.
14. 2 receptor, on tyrosine hydroxylation in rat striatal slices. Life Sci. 42:343-349; 1988.
15. 3 receptor agonists, 7-OH-DPAT and quinpirole, on yawning, stereotypy and body temperature in rats. Pharmacol. Biochem. Behav. 52:503-508; 1995.
16. 2-aminotetralin. Proc. Natl. Acad. Sci. USA 89:8155-8159; 1992.
17. 1 agonist SK&F 38393. Neuropharmacology 25:947-949; 1986.
18. 2 receptors after administration of SND 919 in rats. Naunyn Schmiedebergs Arch. Pharmacol. 340:21-25; 1989.
19. Matsumoto, S.; Yamada, K.; Nagashima, M.; Matsuo, N.; Shirakawa, K.; Furukawa, T. Potentiation by serotonergic inhibition of yawning induced by dopamine receptor agonists in rats. Pharmacol. Biochem. Behav. 32:815-818; 1989.
20. 1 agonist SK&F 38393. Psychopharmacology (Berlin) 95:329-332; 1988.
21. Pellegrino, L. J.; Pellegrino, A. S.; Cushman, A. J. A stereotaxic atlas of the rat brain. New York: Premium Press; 1979.
22. Roth, R. H. Dopamine autoreceptors: Pharmacology, function and comparison with postsynaptic dopamine receptors. Comm. Psychopharmacol. 3:429-445; 1979.
23. 1H])-quinolinone (OPC-4392). Life Sci. 43:263-269; 1988.
24. 3 receptors in vivo. Eur. J. Pharmacol. 218: 373-375; 1992.
25. Setler, P. E.; Sarau, H. M.; Zirkle, C. L.; Saunders, H. L. The central effects of a novel dopamine agonist. Eur. J. Pharmacol. 50:419-430; 1978.
26. Sibley, D. R.; Gonzalez, A. M.; Burgess, L. H.; Max, S. I.; Atkinson, B. N.; Zhang, L. J. Pharmacological characterization of OPC-14597, a novel antipsychotic agent, using cloned dopamine and serotonin receptor. Neuropsychopharmacology 10: 252S; 1994.
27. 3) as a target for neuroleptics. Nature 347: 146-151; 1990.
28. Stahle, L. Do autoreceptors mediate dopamine agonist-induced yawning and suppression of exploration? A critical review. Psychopharmacology (Berlin) 106:1-13; 1992.
29. Stahle, L.; Ungerstedt, U. Yawning and suppression of exploration induced by dopamine agonists: No relation to extracellular striatal levels of dopamine. Pharmcol. Biochem. Behav. 35:204-209; 1990.
30. Stoessl, A. J.; Dourish, C. T.; Iversen, S. D. Apomorphine-induced yawning in rats is abolished by bilatelal 6-hydroxydopamine lesions of substantia nigra. Psychopharmacology (Berlin) 93:336-342; 1987.
31. Stoof, J. C.; Kebabian, J. W. Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci. 35:2281-2296; 1984.
32. Strombom, U. Catecholamine receptor agonists. Effects on motor activity and rate of tyrosine hydroxylation in mouse brain. Naunyn Schmiedebergs Arch. Pharmacol. 292:167-176; 1976.
33. Ushijima, I.; Yamada, K.; Inoue, T.; Tokunaga, T.; Furukawa, T.; Noda, Y. Muscarinic and nicotinic effects on yawning and tongue protruding in the rats. Pharmacol. Biochem. Behav. 21: 297-300; 1984.
34. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-619; 1991.
35. 2 dopamine receptor-mediated inhibition of cyclic AMP formation in striatal neurons in primary culture. Mol. Pharmacol. 27:595-599; 1985.
36. Yamada, K.; Furukawa, T. Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning. Psychopharmacology (Berlin) 67:39-43; 1980.
37. Yamada, K.; Furukawa, T. The yawning elicited by α-melanocyte-stimulating hormone involves serotonergic-dopaminergic-cholinergic neuron link in rats. Naunyn Schmiedebergs Arch. Pharmacol. 316:155-160; 1981.
38. Yamada, K.; Matsumoto, S.; Nagashima, M.; Kumagai, M.; Kimura, H.; Furukawa, T. Involvement of central β-adrenoceptors in the regulation of yawning responses. Naunyn Schmiedebergs Arch. Pharmacol. 340:26-30; 1989.
39. 2 receptors in yawning and stereotypy in rats. Psychopharmacology (Berlin) 100:141-144; 1990.
40. 2 receptor antagonist. Life Sci. 42:1941-1954; 1988.
41. Zarrindast, M. R.; Poursoltan, M. Interactions of drugs acting on central dopamine receptors and cholinoceptors on yawning responses in the rat induced by apomorphine, bromocriptine or physostigmine. Br. J. Pharmacol. 96:843-848; 1989.